 |
 |
 |
| |
One
of IIBR's prime areas of R&D expertise is directed toward
the development and rational design of highly effective
anti-bacterial and anti-viral vaccines.
A wide spectrum of classical as well as state-of-the-
art methodologies, including in-silico and proteomic genome-based
antigen identification, high throughput in-vitro and in-vivo
screening systems, molecular analyses and biophysical
characterization, provide the means to break away from
old-fashioned vaccine paradigms and opens the door to
the development of a new generation of safe, efficacious
and cost-effective vaccines. |
|
| |
The
expertise of our multi-disciplinary R&D teams includes
the production of: |
|
| |
Attenuated
vaccine strains (viral or bacterial)
Subunit vaccines
Purified proteins (native or recombinant)
Recombinant proteins expressed in
live vectors
Hybrid virion vaccines
DNA vaccines
Specific antisera for passive immunotherapy |
|
 |
 |
 |
|
|
|
|
| |
Vaccine
development involves elucidation of diverse vaccine formulations
and delivery systems to establish the means for conferring
efficacious and long-term immunity.
Vaccine evaluation systems are tailored for each pathogen/antigen
of interest and include: |
|
| |
Establishment of optimal in-vitro
or animal model systems
Search for humoral and cellular
correlates of immunity
Determination of vaccine efficacy,
potency and safety |
|
| |
Candidate
vaccine testing for pre-clinical and clinical trials is
carried out according to Good Laboratory Practice (GLP)
laboratory and analysis systems, with up-to- date cGMP materials
produced in the department of biotechnology, for both
phase I and phase II clinical trials. |
|
|
|
|
|
Download this page in PDF format